Validation of the PETS-stroke-A patient reported measure (PRM) of treatment burden after stroke

Martin Taylor-Rowan¹; David T Eton²; Hamish J. McLeod¹; Jala Rizeq¹; Lisa Kidd³; Grace Currie⁴; Terry J Quinn⁵; Frances S Mair¹; Katie I Gallacher¹

Affiliations:

- 1. School of Health and Wellbeing, College of Medical Veterinary and Life Sciences, University of Glasgow, G12 8TB UK
- 2. Outcomes Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda, MD, USA*
- 3. Department of Nursing and Community Health, Glasgow Caledonian University, Glasgow, G40BA, UK
- 4. School of Medicine, University of Glasgow, G12 8TB, UK
- 5. School of Cardiovascular and Metabolic Sciences, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK

Corresponding author: katie.gallacher@glasgow.ac.uk

*Dr. Eton was on staff at the Mayo Clinic (Rochester, MN USA) when this study began. His contributions to this report were made after moving to the National Cancer Institute. The opinions and views expressed by the authors are their own, the content is solely the responsibility of the authors, and this material does not represent the official viewpoint of the US Department of Health and Human Services, the National Institutes of Health, or the National Cancer Institute.

Abstract

Introduction

Treatment burden is the workload of healthcare for people with long-term conditions and the impact on wellbeing. A validated measure of treatment burden for use as an outcome measure in stroke trials is needed. We adapted a patient-reported measure (PRM) of treatment burden in multimorbidity, PETS (Patient Experience with Treatment and Self-Management version 2.0), to create a stroke-specific measure, PETS-stroke, and examined its psychometric properties.

Patients and Methods

We recruited stroke and transient ischaemic attack (TIA) survivors between Feb 2022-June 2023 from 10 hospitals in the UK and through the Scottish Health Research Register (SHARE). Participants completed the PETS-stroke questionnaire along with 3 other PRM's (Stroke Southampton Self-Management Questionnaire, The Satisfaction with Stroke Care Measure, The Shortened Stroke Impact Scale). We performed confirmatory factor analysis to test the factor structure of the PETS-stroke. We assessed Spearman's rank correlations between PETS-stroke and other PRMs to determine convergent validity. Intra-class coefficient was performed to assess test-retest reliability. Proportions of missing data along with feedback from qualitative interviews were used to determine feasibility. T-tests were conducted to examine variations in PETS-stroke scores based on multimorbidity and socioeconomic factors.

Results

Three-hundred-eighty-one participants were included. The best fit was achieved with a 9-factor structure and internal consistency was good (Omega values 0.729 to 0.921). The factor loadings for the individual indicator items across eight of the nine domains were moderate to strong. All domains of PETS-stroke showed moderate to strong correlations with at least one other PRM. Test-retest reliability was good for all domains (ICC>0.7). Qualitative feedback on feasibility was positive and missing data was within acceptable limits for 7 domains. PETS-stroke scores significantly differed based on multimorbidity in 3 domains and in 8 domains based on socioeconomic status.

Discussion

Psychometric performance suggests PETS-stroke is a highly promising measure of treatment burden after stroke.

Key words: Stroke, Treatment Burden, Validity, PETS-stroke

Introduction

The term *treatment burden* describes the healthcare workload of living with long-term conditions and the impact of this work on wellbeing. Treatments can become burdensome when there are too many, or if they are challenging to implement in everyday life. People with stroke describe the healthcare workload as draining of time, energy and finances.¹ Additionally, stroke survivors may have physical, cognitive, or emotional impairments that can impede self-management.² There has been a recent interest in understanding treatment burden and developing methods of measurement, to aid identification of high-risk groups and assist the testing of interventions.³ Understanding these issues in a sufficiently nuanced way will require the creation of condition-specific measures that have been developed and tested in line with best practice principles.⁴

Treatment burden is subjective; therefore, patient-reported methods are suitable for measurement. The Patient Experience with Treatment and Self-Management (PETS) 2.0⁵ is a commonly used patient-reported measure (PRM) of treatment burden; however it was designed for use in a general healthcare population and does not capture key aspects of the stroke treatment burden profile such as rehabilitation strategies for limb weakness or speech difficulties. Despite a distinct care pathway, no comprehensive PRMs of treatment burden in stroke currently exist. Consequently, we are unable to fully appreciate the experience of treatment burden amongst stroke survivors and the impact this may have upon their health outcomes.

To address this issue, we created the PETS-stroke, a highly modified version of the PETS 2.0, to measure treatment burden after stroke. The content development of PETS-stroke has been described previously. Here, we describe the evaluation of the psychometric properties of the tool. Figure 1 presents the full course of PETS-stroke development highlighting the aspects reported here. Establishing the psychometric properties of PETS-stroke will determine whether the tool is ready to be used to measure treatment burden in stroke populations.

Aims and objectives

Through patient surveys and interviews, our primary aims were:

- 1) To determine the factor structure of PETS-stroke (survey).
- 2) To assess the convergent validity of PETS-stroke (survey).
- 3) To assess the reliability of PETS-stroke (survey).
- 4) To assess the feasibility of PETS-stroke (survey and interviews).

Our secondary aims were to:

- 1) Establish known-groups validity of PETS-stroke, comparing PETS-stroke test scores with measures of socioeconomic status and multimorbidity (survey).
- 2) Establish user perspectives on potential alterations to future iterations of the measure (interviews).

[Insert Figure 1]

Patients and Methods

The project was funded by the Chief Scientist Office (CSO) Scotland (HIPS/21/13). Ethical approval was provided by London and Surrey Borders NHS Research Ethics Committee (20/LO/0871). Guidance on PRM development published by the International Society for Quality of Life Research (ISOQOL)⁸ and COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN)⁹ informed the methodology. Details of the methodology can be seen in the study protocol.¹⁰ A summary is given below.

Survey methods

Recruitment

We recruited stroke and transient ischaemic attack (TIA) survivors between Feb 2022-June 2023 from 9 participating hospitals in Scotland, 1 in Wales, and through the Scottish Health Research Register (SHARE).¹¹ Participants were eligible if they fulfilled the following criteria: community dwelling (including retirement housing or sheltered housing); stroke diagnosis (including ischaemic, haemorrhagic, any severity and TIA); over one month since hospital discharge, but less than 1 year post-stroke at time of completing the survey (in order to capture treatment burdens encountered at home rather than in the hospital, those not admitted to hospital were also included); able to read English; and able to complete the paper survey or ask someone to do as a proxy. We used a sampling frame to promote diversity in participant characteristics (age, sex, ethnicity, socioeconomic status, stroke sequalae, time since stroke).

Data collection

Stroke survivors were asked to complete survey packs containing the PETS-stroke measure and three additional PRMs: The Stroke Southampton Self-Management Questionnaire, measuring readiness to self-manage;¹² The Satisfaction with Stroke Care Measure, measuring healthcare satisfaction;¹³ and The Shortened Stroke Impact Scale, measuring illness burden.¹⁴ In addition, self-reported demographic data were requested—details can be seen in the study protocol. ¹⁵

To determine test-retest reliability, the PETS-stroke was sent out a second time 2 weeks after completion of the first questionnaire and returned by the participant as soon as they were able.

Sample Size

Details of our sample size calculation are in our study protocol. In brief, our sample size calculation indicated that we required a total of 340 participants to give a ratio of approximately 10 participants per item and provide a comparable sample to the Confirmatory Factor Analysis (CFA) study of the PETS 2.0.¹⁶

A sample size calculation for follow-up indicated we would require 218 participants to provide questionnaires at both baseline and follow-up.

Missing data

Pre-established scoring rules were followed for respective questionnaires (see **Supplementary materials 1**). For PETS-stroke similar rules were created based on the scoring system of the PETS 2.0 survey.⁵ Each domain is scored separately, and raw scores are standardised to generate scores ranging from 0-100 for each domain. Higher scores indicate greater treatment burden.

'Not applicable' responses were treated as missing values. PETS-stroke domains could be scored and included in analysis, despite missing data, provided >50% of items were answered within the domain. Otherwise, missing/not applicable demographic and questionnaire data were excluded from analyses.

Data analysis

All analyses and assumptions are described in a detailed α priori publicly available Statistical Analysis Plan (https://osf.io/6p2kt/).

Examination of sample characteristics

Sociodemographic characteristics of participants were reported descriptively.

Confirmatory Factor Analysis Model Specification, factor loadings and internal consistency reliability

The PETS-Stroke differed from the PETS-2.0; the scale was shortened to make it more tolerable for the target population and the item content and response scales were adapted based on qualitative data obtained from stroke survivors. The resulting 34-item measure shared some items and underlying theoretical constructs with the original scale. In order to pre-specify the factor structure of the PETS-Stroke, three subject matter experts (two general practitioners and one stroke specialist) independently reviewed the scale items and proposed sub-scale composition. Disagreements were then discussed and if needed the chief investigator of the study had the casting vote where consensus could not be reached (this only occurred on one occasion). Nine subscales were identified based on 33 items from the PETS-Stroke, with one remaining item assessing Mental Fatigue set aside as a single indicator item. The specification of this potential new structure was completed prior to estimating the models.

Based on the theoretical model of treatment burden and previous work on the PETS-2.0¹⁶ scale structure, CFA was used to test competing underlying models to assess the dimensionality of the new PETS-Stroke and identify the best fitting structure that would account for its revised item composition. Four models were estimated: 1) a one factor "treatment burden" model; 2) a bifactor (hierarchical) model with an overall treatment burden factor that loads onto all items and three orthogonal specific measurement factors representing workload, impact, and general burden (underlying items not captured by workload or impact); 3) a nine-factor model of the newly proposed structure; 4) a higher order model with one second order factor of treatment burden underlying the nine first order factors.

As the observed variables are measured on ordinal scales, analyses were conducted on polychoric correlation matrices and robust weighted least squares with adjustment for mean (WLSM) estimator was used. Model fit evaluation used multiple indices (model χ^2 , SRMR<0.08, RMSEA<0.06, TLI/CFI \geq 0.95) in line with best practice guidance. Internal consistency was assessed with McDonald's omega based on realistic assumptions about the covariance between scale items and factors. Analyses were carried out in RStudio (version 2024.04.1+748) using the packages Lavaan (v 0.6-16) and semTools (v 0.5-6).

Evaluation of psychometric properties

To examine convergent validity, the PETS-stroke was compared to the 3 other PRMs using Spearman's rank correlations, hypothesising that higher treatment burden would significantly correlate with lower readiness to self-manage, lower satisfaction with stroke services and increased burden of illness. For domains 'keeping healthy' and 'living at home with stroke', variation in the

number of item responses within each domain skewed missing data imputation. To investigate the impact of this on results, a sensitivity analysis was performed restricting these domains to participants with full data only.

Test-retest reliability was assessed by calculating the intra-class coefficient (ICC) of baseline and follow-up assessments.

T-tests were performed to establish known-groups validity, comparing PETS-stroke test scores with socioeconomic status and multimorbidity. Socioeconomic status was measured using the Scottish Index of Multiple Deprivation (SIMD) and Welsh Index of Multiple Deprivation (WIMD) with scores in lowest and highest quintiles compared. Co-morbidities were self-reported, with a general practitioner interpreting results and generating a count of morbidities for each participant. Multimorbidity was defined as having ≥3 co-morbidities, with scores for this group compared to those with stroke only. We hypothesised that participants from more deprived socioeconomic areas and participants with multimorbidity would have significantly higher treatment burden. A sensitivity analysis was performed using Mann-Whitney U tests to examine known groups analysis to determine any impact of non-normal distribution.

Feasibility Testing

Scores were examined at domain level descriptively using range, means and standard deviations. Percentage of missing items and proportion of returned surveys provided information on acceptability. A total of ≥15% of participants being scored at the lowest or highest possible score for a domain was indicative of a possible floor/ceiling effect.

Semi-structured interviews were conducted by telephone with a subset of participants to enquire about usability of the survey—interview schedule is shown in **Supplementary materials 2**. ²¹ Sampling was purposive, aiming for diversity in age, stroke severity, ethnicity and sex to include a broad range of viewpoints. Interviews were audio recorded and transcribed verbatim. Data was analysed using a codebook thematic analysis approach to look for key themes or topics arising, ²² performed using NVivo software version 14. ²³

User perspectives on potential changes for future iterations

Authors discussed any possible alterations to PETS-stroke guided by the results of psychometric testing. Further interviews were conducted to gauge opinions on these potential changes. The same sampling, qualitative methodology, and analytical approach, described above, was employed.

Results

Sample characteristics

In total 396 participants were recruited. Fifteen were subsequently excluded due to incomplete consent forms, leaving 381 participants available for analysis. Participant demographics are shown in **Table 1**. Demographics were reasonably consistent with Scottish Stroke Care Audit statistics, ²⁴ with the study sample being slightly younger, more affluent, and more able-bodied than the national stroke average.

[insert Table 1]

Factor analysis

Confirmatory Factor Analysis, factor loadings and internal consistency reliability

The CFA fit results including all fit indices are presented in **Table 2**. All models converged normally. A description of models 1,2 and 4 can be found in **Supplementary materials 3**.

[insert Table 2]

Model 3 was based on the assessment of our subject matter experts and this produced the best fitting model with all good or excellent values for all fit indices. **Table 3** provides the subscale names and items and we have presented more details on the model properties in the following sections.

The ω values for the nine domain scores ranged from 0.729 to 0.921 – all well above the thresholds required for acceptable (0.65) to strong (0.80) internal consistency. The factor loadings for the individual indicator items across eight of the nine domains were moderate to strong. Two items in the "Living at Home with Stroke" domain showed factor loadings lower than .40.

[insert Table 3]

Test re-test reliability

Three hundred participants completed the PETS-stroke follow-up questionnaire. Test-retest reliability of the PETS-stroke was good for all domains (ICC>0.7). (**Table 4**)

Construct validity

PETS-stroke domains were significantly correlated with measures of related constructs. Most domains of PETS-stroke demonstrated moderate correlations (Rho=0.4-0.59) with measures of stroke impact, and readiness to self-manage, and weak correlations (Rho=0.2-0.39) with satisfaction with care (**Table 4**). These correlations were consistent with our hypothesis that increased levels of treatment burden would be correlated with lower readiness to self-manage, lower satisfaction with stroke services and increased burden of illness, supporting the validity of the PETS-stroke.

Sensitivity analysis restricting analysis of domains 'keeping healthy' and 'living at home with stroke' to participants with full data only was fully consistent with our primary analysis (**Supplementary materials 4**).

[insert Table 4]

Known group validity

Higher treatment burden on PETS-stroke was significantly associated with poorer sociodemographic status in 8 out of 10 domains (**Table 5**). Participants from the most socioeconomically deprived areas had significantly higher treatment burden scores than participants from the least deprived areas, apart from in the 'Medical information' and 'Role Limits' domains. Participants who had 3 or more ongoing medical conditions had significantly higher treatment burden scores than those who had no co-morbidities in domains of Care Planning, Keeping Healthy, and Difficulty with Healthcare Services, but not in Mental Fatigue, Medical Information, Medications, Medical Appointments, Living at Home with Stroke, Relationships with Others, or Role Limits. (**Table 5**) Sensitivity analysis using Mann-Whitney U tests produced similar results. (**Supplementary materials 5**)

[insert Table 5]

Feasibility

Median reported duration to complete PETS-stroke was 15 (IQR=20) minutes, 108 participants (30%) reported engaging help to complete the questionnaire packs. A description of scores and missing data for each domain is shown in **Table 6**. For baseline assessment, number of missing items were within acceptable limits for 7/10 domains (**Table 6**). Living at home with stroke, Relationships with Others, and Role Limits had substantial missing items which prohibited scoring due to frequent selection of the 'not applicable' option. Possible floor effects were apparent for 5/10 domains (Medical Information, Care Planning, Medications, Medical Appointments, Difficulty with Healthcare Services). No domains demonstrated any ceiling effects. Feasibility data from follow-up assessments were consistent with baseline assessments and can be seen in **Supplementary materials 6**.

Thirty-one participants were interviewed. Participant demographics for the qualitative interviews can be found in **Supplementary material 7**.

Participants found the survey to be quick and easy to complete, with pen and pencil preferred [exemplar quotes: "...all quite self-explanatory. I didn't have any problems"; "I would suggest the handwritten bit is better, especially for, eh, eh, well, a lot of people aren't computer oriented"], though some suggested a digital option may be useful [exemplar quotes: "sometimes I forget to look to my left, and then I've, I've realised there's whole sections missing.....because I use my phone a lot, and I can make it big print.....and it can actually speak to me, if you get what I mean"; "would have happily filled it in online, I suppose that might have been easier to get back to you as well, if you know, if I couldn't get to a post-box"]. The items contained within the questionnaire were important and relevant, but less relevant to those with mild stroke [exemplar quotes: "most of them were, yes.....I wouldn't say none of them were, but I think the whole lot of them were kind of pretty relevant"; "I wasn't required to have anything like that when....after the stroke....some of them more relevant than others"], and no important items were missing [exemplar quotes: "everything there, it compares, it compares to what I've, what I'm doing, what I've went through. And I'm finding the questionnaire, if the truth be told, I can't think of anything else that I would really want to add to it"].

The questions were straightforward to understand but more difficult for those experiencing ongoing cognitive issues [exemplar quotes: "I'm very aware of the consequences of the stroke, so my sort of mental acuity, or cognitive ability has diminished radically.....if I didn't understand the question, I could get (my partner) to explain it to me before I answered"]. Participants reported that the PETS-stroke provided them with a voice to express their opinions on their healthcare [exemplar quotes: "I don't know about anybody else, but I felt as if there wasn't a voice, if you get my meaning...."].

[insert Table 6]

Changes to PETS-stroke and follow up content validity testing

Ten participants took part in cognitive interviews to discuss potential changes to the PETS-stroke. The potential changes discussed and results of analysis of the interviews are shown in **Supplementary materials 8 & 9**. Consensus was reached amongst authors that the resultant changes required were non-substantial, and that further testing was not required before recommendation of PETS-stroke as a valid tool.

Discussion

Summary and research in context

Our results support the validity of the PETS-stroke as a measure of treatment burden after stroke. Each domain of PETS-stroke demonstrated moderate to large correlations with at least one other self-report measure of stroke impact or care. The measure showed adequate test-retest reliability and internal consistency and was deemed acceptable and feasible to complete by stroke survivors. In the majority of domains, a higher level of treatment burden was reported in those who were more socioeconomically disadvantaged, similar to what has been demonstrated in other long-term conditions. However, in the majority of domains treatment burden was not significantly higher in stroke survivors with multimorbidity. While the literature on this association has been mixed, it is possible that these findings arose due to our low-fidelity method of measuring multimorbidity, necessary due to the limited range of multimorbidity within the study sample.

The factor structure that emerged for PETS-stroke differed to that observed in the PETS 2.0. In addition to 12 multi-item factors, the PETS 2.0 had 2 higher order factors reflecting healthcare workload and impact of workload;¹⁶ however, because of the refinement and adaptation of the PETS scale items to make them suitable for measuring treatment burden in stroke, it is unsurprising that the factor structure of this new scale differs from the original. This likely reflects the differing care pathway that stroke survivors experience relative to the multimorbid population. This emphasises the value of using a bespoke measure of treatment burden within the stroke population and suggests the PETS-stroke represents a distinct scale to the PETS 2.0, despite the PETS 2.0 serving as the basis for its design. Face validity testing had suggested that PETS-stroke is most relevant to those within one year of stroke, due to the emphasis on stroke rehabilitation. This work therefore tested the measure in that population. It is possible that measures developed for people with multimorbidity would be suitable for stroke survivors who experienced stroke a longer time ago if they are more focussed on the long-term management of their stroke alongside other conditions.

Recently there have been several comprehensive patient-reported measures of treatment burden developed for use in multimorbidity, ²⁷ however PETS-stroke is the first stroke-specific measure. ²⁸ The PETS measure has been adapted for use in other contexts, for example for use in the homeless population ²⁹ and in kidney transplant patients. ³⁰ The development of a stroke-specific measure will allow inclusion of treatment burden as a case mix adjustor or outcome measure in clinical trials of stroke rehabilitation therapies. Improving the stroke patient experience was found to be a top ten priority in the recent James Lind Alliance priority seeking exercise in stroke. ³¹ Previous research on patient experience in stroke has not tended to focus on treatment burden, rather on satisfaction with healthcare and unmet needs. ³²

Strengths, limitations and future research

We have conducted a comprehensive evaluation of key psychometric properties of the PETS-stroke, surpassing the required sample size for all planned analyses. A key strength of our study is the range of disabilities and socioeconomic status reported by participants which will maximise the generalisability of the measure to the wider stroke population. Moreover, the content of this study aligns with the stroke survivor perspective, and involvement of primary care and stroke clinicians in the measure's development enhances its potential for 'real world' use. PETS-stroke has been developed for use as a research tool, but future research could amend it for clinical use—this has been conducted with the original PETS measure.³³

We did not assess responsiveness to change which is an important psychometric property necessary for assessing the impact of interventions, future work will address this.

The ethnic diversity of the sample population is limited. We therefore cannot say how well the PETS-stroke can be used by people whose first language is not English, or if there is any variability based upon cultural background.

Factor analysis revealed two items in the 'living at home with stroke' domain below optimal parameters, suggesting they could fit sub optimally in PETS-stroke. This domain also had a high proportion of participants ticking 'not applicable'. Face validity testing had revealed these items to be irrelevant to some stroke survivors yet important to include in the measure. Future work should examine the sensitivity of the scale structure with and without those items.

Floor effects were apparent for half the items in the measure. This is likely a consequence of the study population being higher functioning than the typical stroke population. This may also explain some domains having a high number of 'not applicable' answered by participants. Similar floor effects have been seen with the development of other treatment burden measures.³⁴

The variation in scale length for 2 of the PETS-stroke domains led to a minor skew of imputed scores, wherever data was missing. While our sensitivity analysis indicates that this skew did not have any meaningful impact upon our reported results, this issue should be addressed for future versions of PETS-stroke.

Our measure of multimorbidity was suboptimal and so findings of known groups validity testing in relation to that should be interpreted with caution. Further examination of treatment burden after stroke in relation to patient characteristics is important to identify those at high risk.

Conclusions

In conclusion, our results indicate that the PETS-stroke is a valid measure of treatment burden in community dwelling stroke survivors. This new PRM has the potential to ascertain if treatments are workable for patients in the context of their everyday lives. Details of how the scale can be accessed and used can be found at http://tiny.cc/jgrlzz.

References

- 1. Gallacher K, Morrison D, Jani B, et al. Uncovering treatment burden as a key concept for stroke care: a systematic review of qualitative research. *PLoS Med* 2013; 10: e1001473. 2013/07/05. DOI: 10.1371/journal.pmed.1001473.
- 2. Gallacher KI, May CR, Langhorne P, et al. A conceptual model of treatment burden and patient capacity in stroke. *BMC Fam Pract* 2018; 19: 9. 2018/01/11. DOI: 10.1186/s12875-017-0691-4.
- 3. Mair FS and May CR. Thinking about the burden of treatment. *BMJ* 2014; 349: g6680. 2014/11/12. DOI: 10.1136/bmj.g6680.
- 4. Rosellini AJ and Brown TA. Developing and Validating Clinical Questionnaires. *Annu Rev Clin Psychol* 2021; 17: 55-81. 2021/02/10. DOI: 10.1146/annurev-clinpsy-081219-115343.
- 5. Eton DT, Yost KJ, Lai JS, et al. Development and validation of the Patient Experience with Treatment and Self-management (PETS): a patient-reported measure of treatment burden. *Qual Life Res* 2017; 26: 489-503. 2016/08/28. DOI: 10.1007/s11136-016-1397-0.
- 6. Wood K, Sardar A, Eton DT, et al. Adaptation and content validation of a patient-reported measure of treatment burden for use in stroke survivors: the patient experience with treatment and self-management in stroke (PETS-stroke) measure. *Disabil Rehabil* 2024; 46: 3141-3150. 2023/08/07. DOI: 10.1080/09638288.2023.2241360.
- 7. Gallacher K, Sardar A, Kidd L, et al. Adaptation and Content Validation of a Patient-Reported Measure of Treatment Burden for use in Stroke Survivors (PETS-Stroke). *Ann Fam Med* 2023; 21 2023/03/28. DOI: 10.1370/afm.21.s1.3647.
- 8. Reeve BB, Wyrwich KW, Wu AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. *Qual Life Res* 2013; 22: 1889-1905. 2013/01/05. DOI: 10.1007/s11136-012-0344-y.
- 9. Mokkink LB, Prinsen CA, Bouter LM, et al. The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) and how to select an outcome measurement instrument. *Braz J Phys Ther* 2016; 20: 105-113. 2016/01/21. DOI: 10.1590/bjpt-rbf.2014.0143.
- 10. Gallacher KI, Taylor-Rowan M, Eton DT, et al. Protocol for the development and validation of a patient reported measure (PRM) of treatment burden in stroke. *Health Open Res* 2023; 5: 17. 2024/05/06. DOI: 10.12688/healthopenres.13334.2.
- 11. SHARE The Scottish Health Research Register and Biobank, https://www.registerforshare.org/ (2023).
- 12. Boger EJ, Hankins M, Demain SH, et al. Development and psychometric evaluation of a new patient -reported outcome measure for stroke self -management: The Southampton Stroke Self Management Questionnaire (SSSMQ). *Health Qual Life Outcomes* 2015; 13: 165. 2015/10/04. DOI: 10.1186/s12955-015-0349-7.
- 13. Guimaraes Marcelino CA, Monteiro da Cruz D and Rueda LJ. The efficacy of telephone use to assist and improve the wellbeing of family caregivers of persons with chronic diseases: a systematic review protocol. *JBI Database of Systematic Reviews & Implementation Reports* 2013; 11: 330-342. DOI: 10.11124/01938924-201311020-00005.
- 14. MacIsaac R, Ali M, Peters M, et al. Derivation and Validation of a Modified Short Form of the Stroke Impact Scale. *J Am Heart Assoc* 2016; 5 2016/05/22. DOI: 10.1161/JAHA.115.003108.
- 15. Edwards P, Roberts I, Clarke M, et al. Increasing response rates to postal questionnaires: systematic review. *BMJ* 2002; 324: 1183. 2002/05/23. DOI: 10.1136/bmj.324.7347.1183.
- 16. Lee MK, St Sauver JL, Anderson RT, et al. Confirmatory Factor Analyses and Differential Item Functioning of the Patient Experience with Treatment and Self-Management (PETS vs. 2.0): A Measure of Treatment Burden. *Patient Relat Outcome Meas* 2020; 11: 249-263. 2021/01/16. DOI: 10.2147/PROM.S282728.

- 17. Hu L-t, & Bentler, P. M. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. *Structural Equation Modeling* 1999; 6: 1-55.
- 18. Flora. Your Coefficient Alpha Is Probably Wrong, but Which Coefficient Omega Is Right? A Tutorial on Using R to Obtain Better Reliability Estimates. *Advances in Methods and Practices in Psychological Science* 2020; 3: 484-501.
- 19. McNeish D. Thanks coefficient alpha, we'll take it from here. *Psychol Methods* 2018; 23: 412-433. 2017/05/31. DOI: 10.1037/met0000144.
- 20. Revelle W and Condon DM. Reliability from alpha to omega: A tutorial. *Psychol Assess* 2019; 31: 1395-1411. 2019/08/06. DOI: 10.1037/pas0000754.
- 21. Hennink M and Kaiser BN. Sample sizes for saturation in qualitative research: A systematic review of empirical tests. *Soc Sci Med* 2022; 292: 114523. 2021/11/18. DOI: 10.1016/j.socscimed.2021.114523.
- 22. Braun V CV. Using thematic analysis in psychology. *Qualitative research in psychology*. 2nd Ed. ed.: London: Routledge, 2006, pp.77-101.
- 23. Lumivero. NVivo (Version 14), <u>www.lumivero.com</u> (2023).
- 24. Statistics SS. A National Statistics publication for Scotland, https://publichealthscotland.scot/publications/scottish-stroke-statistics/scottish-stroke-statistics-year-ending-31-march-2021/ (2021).
- 25. Morris JE, Roderick PJ, Harris S, et al. Treatment burden for patients with multimorbidity: cross-sectional study with exploration of a single-item measure. *Br J Gen Pract* 2021; 71: e381-e390. 2021/04/21. DOI: 10.3399/BJGP.2020.0883.
- 26. Eton DT, Lee MK, St Sauver JL, et al. Known-groups validity and responsiveness to change of the Patient Experience with Treatment and Self-management (PETS vs. 2.0): a patient-reported measure of treatment burden. *Qual Life Res* 2020; 29: 3143-3154. 2020/06/12. DOI: 10.1007/s11136-020-02546-x.
- 27. Mendoza-Quispe D, Perez-Leon S, Alarcon-Ruiz CA, et al. Scoping review of measures of treatment burden in patients with multimorbidity: advancements and current gaps. *J Clin Epidemiol* 2023; 159: 92-105. 2023/05/23. DOI: 10.1016/j.jclinepi.2023.05.013.
- 28. Gallacher KI, Quinn T, Kidd L, et al. Systematic review of patient-reported measures of treatment burden in stroke. *BMJ Open* 2019; 9: e029258. 2019/09/20. DOI: 10.1136/bmjopen-2019-029258.
- 29. Jones C, Mair FS, Williamson AE, et al. Treatment burden for people experiencing homelessness with a recent non-fatal overdose: a questionnaire study. *Br J Gen Pract* 2023; 73: e728-e734. 2023/07/11. DOI: 10.3399/BJGP.2022.0587.
- 30. Lorenz EC, Petterson TM, Zaniletti I, et al. Development and Validation of a Kidney-Transplant Specific Measure of Treatment Burden. *BMC Nephrol* 2022; 23: 301. 2022/09/04. DOI: 10.1186/s12882-022-02923-3.
- 31. Hill G, Regan S, Francis R, et al. Research priorities to improve stroke outcomes. *Lancet Neurol* 2022; 21: 312-313. 2022/03/20. DOI: 10.1016/S1474-4422(22)00044-8.
- 32. Abu Saydah H, Turabi R, Sackley C, et al. Stroke Survivor's Satisfaction and Experience with Rehabilitation Services: A Qualitative Systematic Review. *J Clin Med* 2023; 12 2023/08/26. DOI: 10.3390/jcm12165413.
- 33. Eton DT, Yost KJ, Ridgeway JL, et al. Development and acceptability of PETS-Now, an electronic point-of-care tool to monitor treatment burden in patients with multiple chronic conditions: a multi-method study. *BMC Prim Care* 2024; 25: 77. 2024/03/02. DOI: 10.1186/s12875-024-02316-5.
- 34. Duncan P, Scott LJ, Dawson S, et al. Further development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ). *BMJ Open* 2024; 14: e080096. 2024/04/12. DOI: 10.1136/bmjopen-2023-080096.

Tables

Table 1. Baseline demographics

Demographic	Number of valid cases (total=381)	Study descriptive data	National data- at first stroke assessment (n=11,257)
Age (Mean; SD)	371	68.2 (11.24)	73
Gender (Female %*)	378	43.3%	47%
Ethnicity (%*)	379	White: 98.4% Asian: 0.8% Black: 0.3% Other ethnic group: 0.3%	Not available
Education (%*)	370	None: 17.3% School qualifications: 35.6% Higher education: 46.8%	Not available
Number of co-morbidities (Mean; SD)	379	2.2 (1.9)	Not available
Medication count (Mean; SD)	375	5.8 (3.1)	Not available
Deprivation quintile (%*)	372	1 st (Most deprived): 17.5% 2 nd : 18.8% 3 rd : 17.2% 4 th : 22.8% 5 th (Least deprived): 23.1%	1 st (Most deprived): 24% 2 nd : 22% 3 rd : 20% 4 th : 18% 5 th (Least deprived): 16%
Speech difficulties (%*)	380	20.3%	29%
Difficulty using arms (%*)	380	26.3%	39%
Difficulty walking (%*)	380	41.3%	55%
Wheelchair use (%*)	380	1.6%	Not available
Live alone (%*)	379	26.3%	Not available
Have support with chores if needed (%*)	374	92.2%	Not available
Participating in other research or trial (%)	376	18.1%	Not available

^{*}Percentages are rounded so ≠ 100%

Table 2 PETS-Stroke CFA model fit results (N= 378)

Models	χ^2	df	CFI	TLI	RMSEA	90%	SRMR
						CI	
Model 1: Single Factor Model	6708.0	495	0.891	0.884	0.182	0.178-	0.133
						0.187	
Model 2: Bifactor Model	2752.7	462	0.96	0.954	0.115	0.11-	0.095
						0.12	
Model 3: Nine Factor Model	1710.0	459	0.978	0.975	0.085	0.079-	0.085
						0.091	
Model 4: Higher Order Nine	2018.2	486	0.973	0.971	0.091	0.086-	0.092
Factor Model						0.097	

Notes: All χ 2 results are statistically significant (p < .001); χ 2 = chi-square test; df = degrees of freedom; CFI = Comparative Fit Index (> 0.90 = adequate fit, > 0.95 = excellent fit); TLI = Tucker-Lewis Index (> 0.90 = adequate fit, > 0.95 = excellent fit); RMSEA = Root Mean Square Error of Approximation (< 0.08 = adequate fit, < 0.06 = excellent fit); SRMR = Standardised Root Men Square Residual (<0.1 = acceptable; <0.08 = good). Best-fitting model in **bold**

Table 3 PETS-Stroke Factor Loadings and internal consistency for the 9 Factor (Best Fitting) Model

Factor (McDonald's omega)	Item	Factor Loading
Medical	How easy or difficult has it been for you to	
Information	now easy or announcings to seem for you to	
$(\omega = 0.818)$		
(65 0.010)	Learn about and understand information about your stroke, other health	0.907
	problem(s) and recommended treatments? (SMINF1)	
	Find sources of medical information e.g. a healthcare professional that you	0.836
	trust? (MINF6)	
Care Planning	How easy or difficult has it been for you to	
$(\omega = 0.901)$	Set goals for your recovery or to stay healthy? (SCP1)	0.961
	Stay motivated to improve or maintain your health and functioning? (SCP2)	0.917
Medications	How easy or difficult has it been for you to	
$(\omega = 0.852)$	Get repeat prescriptions? (SMED2)	0.682
	Take your medicines as directed? (SMED3)	0.943
	Cope with adjustments to your medicines made by healthcare	0.916
	professionals (for example the amount, type, or time when you take it)? (SMED4)	
	Organize your medicines at home? (MED1)	0.942
	How bothered have you been by side effects of your medicine(s)? (MSB)	0.421
Medical Appointments	(H)ow easy or difficult has it been for you to	
$(\omega = 0.874)$	Physically get to the clinic for your appointments for example due to	0.841
(6 - 0.674)	disability or transport issues? (SMAP)	0.041
	Schedule and keep track of your medical appointments? (MAP2)	0.913
	Find the time to get to your medical appointments? (MAP4)	0.858
Keeping	Thinking about what you might do to take care of your	0.966
Healthy	health, how easy or difficult has it been for you to[M]onitor	
$(\omega = 0.898)$	your health, for example hand and arm functions, weight,	
,	signs of another stroke or anything else? (SMH1)	
	It is hard for me to follow a healthy lifestyle e.g. healthy diet (either self-	0.620
	directed or recommended by a health care provider). (SLIF1R)	
	How much do you agree or disagree with the	
	following statements?	
	I have other medical conditions or symptoms such as pain, shortness of	0.770
	breath or memory issues that make it difficult for me to take part in my	
	stroke rehabilitation therapies or look after my health (SPTR)	
	It is difficult for me to follow exercise or physical therapy regimes (either	0.759
	self-directed or recommended by a health care provider). (PT2R)	
Living at Home with	How much do you agree or disagree with the following statements?	
Stroke	It is difficult to obtain mobility side (such as a wheelsheir as welling stick) as	0.446
$(\omega = 0.792)$	It is difficult to obtain mobility aids (such as a wheelchair or walking stick) or	0.416
	home adaptations (such as a bath rail or ramp). (SLIV1R) It is difficult to organize home carers or personal care services. (SLIV2R)	0.357
	It is difficult to organize nome carers or personal care services. (SLIVZR) It is difficult to obtain financial aid from the government (benefits).	0.357
	it is difficult to obtain financial aid from the government (benefits).	0.231

	(SLIV3R)	
	Thinking about your healthcare needs, how easy or difficult has it been for you to	
	Pay for healthy living (e.g. foods, exercise)? (SMEXP1) Pay for walking aids or changes to your home such as a ramp? (SMEXP3) Pay for your medicines, if there are any not already covered by the NHS e.g. over the counter medications? (MEXP4)	0.966 0.723 0.697
Relationships with Others	How bothered have you been by	
$(\omega = 0.729)$	Feeling dependent on others for your healthcare needs? (RLO1) Your healthcare needs creating tension in your relationships with others? (RLO3)	0.786 0.812
Difficulty with Healthcare Services	Thinking about your health care, how much do you agree or disagree with the following statements?	
$(\omega = 0.921)$	Health professionals give me conflicting advice. (SHCS2R) I don't feel involved enough in decisions made about my health and care. (SHCS3R)	0.870 0.893
	I have problems getting to see the right health professional (e.g. GP, therapist or consultant) at times that are convenient for me. (SHCS4R)	0.794
	I have not been offered enough therapy to recover from my stroke or maintain my health such as physiotherapy. (SHCS5R)	0.747
	My discharge from hospital was poorly planned by health professionals (e.g. inadequate follow up care). (SHCS6R)	0.727
	I have problems with different healthcare providers not communicating with each other about my medical care. (HCS1R)	0.811
Role Limitations	How much has looking after your health impacted your	
$(\omega = 0.751)$	Usual roles, responsibilities and activities, for example employment, caring duties or hobbies? (SRAL1)	0.677
	Gain support in your return to employment or other roles. (SRAL2)	0.846
	Find out about and pain appropriate patrons to deliving (CDAL2)	0.004

Table 4. Correlations between PETS-stroke and other PRM's and test-retest reliability of PETSstroke

Find out about and gain support in return to driving. (SRAL3)

0.684

PETS-stroke	SIS	SSMQ	PSQ	Test-
domain				retest
				ICC
Medical	-0.482**	-0.554**	-0.402**	0.754
Information				
Care Planning	-0.564**	-0.607**	-0.324**	0.796
Medications	-0.353**	-0.377**	-0.237**	0.817
Medical	-0.559**	-0.463**	-0.302**	0.799
appointments				
Keeping	-0.564**	-0.594**	-0.356**	0.821
Healthy				
Living at Home	-0.428**	-0.503**	-0.330**	0.835
with Stroke				
Relationships	-0.586**	-0.453**	-0.226**	0.776
with Others				
Difficulty with	-0.488**	-0.588**	-0.521**	0.827
Healthcare				
services				
Role Limits	-0.671**	-0.463**	-0.365**	0.848
Mental Fatigue	-0.604**	-0.452**	-0.248**	0.807

Spearman's Rho; **correlation significant at 0.01 level (two-tailed)

SSSQ: The Stroke Southampton Self-Management Questionnaire

PSQ: The Satisfaction with Stroke Care Measure

SIS: The Shortened Stroke Impact Scale

PRM: Patient Reported Measure

ICC: intra-class coefficient

Table 5. Difference in PETS-stroke domain scores based on socioeconomic and multimorbidity factors

Socioeconomic status

PETS-stroke domain	Number in highest deprivation SIMD/WIMD quintile	Number in lowest deprivation SIMD/WIMD quintile	Mean difference	95%CI	P-value (two- sided)
Medical Information	60	79	6.28	-1.78 to 14.33	0.126
Care Planning	66	81	13.10	4.36 to 21.84	<0.01**
Medications	66	84	5.95	0.24 to 11.66	0.04*
Medical appointments	62	76	16.00	7.60 to 24.38	<0.01**
Keeping Healthy	59	71	12.02	5.82 to 18.21	<0.01**
Living at Home with Stroke	21	14	16.36	4.48 to 28.24	<0.01**
Relationships with Others	48	54	18.52	7.18 to 29.85	<0.01**
Difficulty with Healthcare services	65	80	7.30	0.31 to 14.30	0.04*
Role Limits	37	58	9.94	-1.76 to 21.63	0.09
Mental Fatigue	64	83	12.58	4.35 to 20.82	<0.01**
Multimorbidity					
PETS-stroke	Number with	Number with ≥3 co-	Mean	95%CI	P-value
domain	stroke only	morbidities	difference		(two- sided)
Medical Information	60	131	-3.53	-10.76 to 3.71	0.337
Care Planning	63	134	-8.19	-16.33to -0.45	0.049*
Medications	65	139	-1.97	-7.54 to3.61	0.488
Medical appointments	62	134	-2.55	-9.79 to 4.69	0.488
Keeping Healthy	62	124	-6.09	-12.01 to -0.18	0.043*
Living at Home with Stroke	20	37	3.61	-7.57 to 14.79	0.520
Relationships with Others	44	104	-6.86	-17.37 to 3.65	0.199
Difficulty with Healthcare services	62	134	-8.22	-14.87 to -1.58	0.016*
Role Limits	49	83	-6.75	-15.72 to 2.23	0.139


Mental Fatigue	64	133	-8.14	-16.66	0.061
				to 0.377	

Table 6. Baseline PETS-stroke descriptives

PETS-stroke	N baseline	Mean	Score	Missing (%)	% lowest	% highest
domain	(total=381)	score (SD)	Range		score	score

Medical Information	351	30 (23)	0-100	8%	22.8%	0.3%
Care Planning	361	37 (27)	0-100	5%	19.4%	2.8%
Medications	373	21 (19)	0-85	2%	22.0%	0.8%
Medical appointments	353	31 (25)	0-100	7%	19.5%	2%
Keeping Healthy	329	35 (18)	0-83	14%	5.8%	0%
Living at Home with Stroke	89	47 (19)	0-97	77%	1.1%	0%
Relationships with Others	258	41 (31)	0-100	32%	15.9%	7.8%
Difficulty with Healthcare Services	363	35 (22)	0-100	5%	12.9%	0.8%
Role Limits	241	49 (28)	0-100	37%	8.3%	6.2%
Mental Fatigue	368	45 (26)	0-100	3%	13.0%	4.6%

Figure 1. PETS-stroke development stages



PETS = Patient Experience with Treatment and Self-Management Measure